Merck KGaA to buy Bio-Techne for $11.3bn in life science footprint expansion

Merck KGaA has agreed to get beingness sciences institution Bio-Techne Corporation for $11.3bn, representing 1 of the largest fiscal outlays by a drugmaker truthful acold this year.

As per the deal, Merck volition wage $73 for each of Bio-Techne's US-listed shares, representing a 36% premium to the company's one-month measurement weighted mean trading price. The connection is simply a 25% premium to Bio-Techne's past marketplace adjacent of $58.88 connected 24 June.

Bio-Techne, which is headquartered successful the US but has a important planetary presence, develops and manufactures beingness subject reagents, analytical instruments, and objective diagnostics. The institution besides supplies proteins, antibodies, and tiny molecules utilized successful cause development.

Bio‑Techne operates successful 34 locations worldwide and employs astir 3,100 people. In fiscal twelvemonth 2025, the institution generated implicit $1.2bn successful nett sales.

Merck said the takeover would assistance enactment customers from the find and translational probe signifier done to development, investigating and commercialized manufacturing. The German drugmaker besides said Bio-Techne would bring a "recognised portfolio of cytokines, maturation factors, antibodies, and immunoassay kits."

The woody is Merck's largest since it spent $17bn connected acquiring Sigma-Aldrich, besides a beingness sciences instrumentality manufacturer, successful 2015. Both the Bio-Techne and Sigma-Aldrich takeovers are portion of Merck's ongoing strategy to grow its already salient footprint successful the beingness sciences assemblage and trim gross reliance solely connected marketed drugs.

The acquisition marks the archetypal nether the ticker of caller CEO Kai Beckmann, who took implicit from Belén Garijo successful September 2025. In May this year, Beckmann described the company's pipeline arsenic "rather slim" successful a league call, pledging a absorption connected M&A to bolster merchandise offerings.

Commenting connected the Bio-Techne deal, Beckmann said: "This transaction is an important milestone towards delivering connected our mid- to semipermanent strategical agenda. Bio-Techne is an outstanding acceptable that straight supports our strategical absorption focused connected delivering cutting-edge products and solutions crossed the full manufacture worth concatenation – from laboratory customers to those manufacturing successful the biotech and pharmaceutical industries."

Compared to different large pharma companies, Merck has been connected the quieter broadside of dealmaking – its $3.9bn acquisition of SpringWorks Therapeutics successful April 2025 was its largest successful years. Buoyed by biopharma manufacture optimism, Mercks outlay connected Bio-Techne could signify the commencement of a caller M&A impetus nether Beckmann.